Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
REPL Transcript
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript
Unknown5-23
The earnings call reveals significant financial strain with increasing net losses and operational costs, despite a rise in cash reserves. The absence of a share repurchase program and unclear management responses during the Q&A further contribute to uncertainty. While there is optimism around the RP1 launch and regulatory progress, the lack of specific revenue guidance and potential commercial launch risks weigh negatively. Overall, the financial performance and operational challenges suggest a negative sentiment, likely leading to a stock price decline between -2% to -8%.
Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. Financial performance shows a net loss increase and rising expenses, which is negative. However, cash reserves increased, indicating good capital management. Product development updates, such as breakthrough designation and consistent FDA engagement, are positive. However, management avoided revenue guidance, creating uncertainty. The Q&A reveals a broad adoption expectation and manufacturing readiness, but concerns about supply chain challenges and unclear market strategies persist. Overall, the sentiment is balanced, leading to a neutral prediction.
Replimune (REPL) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
Neutral1-12
REPL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
